期刊论文

Kashanchi, F

英文

Pharmaceuticals

1424-8247

2024

17

1

33-

10.3390/ph17010033

Conceptualization, P.K., S.F.J.L.G. and F.K.; methodology, P.K., S.N., Y.Z., F.A.A., C.Z., G.M., Y.K., M.C., Y.Z., A.W., S.F.J.L.G. and F.K.; software, P.K., S.N., Y.K., Y.Z. and C.Z.; validation, P.K., Y.Z. and C.Z.; formal analysis, P.K., Y.Z. and F.K.; investigation, F.K. and P.K.; resources, F.K., Y.Z., F.A.A. and S.F.J.L.G.; data curation, P.K. and F.K.; writing—P.K.; editing—P.K. and F.K.; visualization, P.K., S.N., C.Z. and F.K.; supervision, F.K.; project administration, F.K.; funding acquisition, F.K. and Y.Z. All authors have read and agreed to the published version of the manuscript. This work was supported by “Targeted Pharmaceuticals (GMU#223390)” and “National Institutes of Health (NIH) Grants (AI078859, AI074410, AI127351-01, AI043894, NS099029, and DA050176)” to F.K., and the “National Natural Science Foundation of China (grant No. 12175081) and Fundamental Research Funds for the Central Universities (grant No. CCNU22QN004)” to Yunjie.

本校为其他机构

The HIV-1 transactivator protein Tat interacts with the transactivation response element (TAR) at the three-nucleotide UCU bulge to facilitate the recruitment of transcription elongation factor-b (P-TEFb) and induce the transcription of the integrated proviral genome. Therefore, the Tat–TAR interaction, unique to the virus, is a promising target for developing antiviral therapeutics. Currently, there are no FDA-approved drugs against HIV-1 transcription, suggesting the need to develop novel inhibitors that specifically target HIV-1 transcripti...